{"entity":{"id":"nct00539591","kind":"trial","name":"Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma","aka":[],"tldr":"A phase 2 trial of Peginterferon alfa-2b and Temozolomide in Melanoma, run by St. Jude Children's Research Hospital, active and no longer recruiting.","summary":"Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma is a phase 2 interventional study registered as NCT00539591 by St. Jude Children's Research Hospital, with 29 participants planned, started 2008-05-09 and due to reach its primary completion in 2015-06. Interventions recorded: Peginterferon alfa-2b, Temozolomide, Recombinant interferon alfa-2b. Conditions recorded: Malignant Melanoma.\n\nLinked to the drug Peginterferon alfa-2b because the registry names it among its interventions and Melanoma among its conditions. Registry record only: no result has been read by an editor.","status":"active","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT00539591","url":"https://clinicaltrials.gov/study/NCT00539591"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":["peginterferon-alfa-2b","temozolomide"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT00539591","phase":"2","setting":"Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma","sponsor":"St. Jude Children's Research Hospital","enrolled":29,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct00539591/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"drug":[{"id":"peginterferon-alfa-2b","kind":"drug","name":"Peginterferon alfa-2b","route":"/drugs/peginterferon-alfa-2b/"},{"id":"temozolomide","kind":"drug","name":"Temozolomide","route":"/drugs/temozolomide/"}]}}